CRISPR Therapeutics Announces Two Presentations

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-Thalassemia

BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two presentations during the 58 th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA on December 3 rd -6 th , 2016. 

The two presentations will highlight recent work in re-creating the natural condition of hereditary persistence of fetal hemoglobin (HPFH) that is protective in sickle cell disease and beta thalassemia.  The presentations will describe the ability to re-create specific HPFH gene variants in the intended target tissue, human primary CD34 + stem cells, and the effect of these gene variants at re-creating the expression of protective fetal hemoglobin.  Additional data on progress towards filing an IND or CTA will also be presented.   

“We are excited by our progress and we remain focused on our goal of bringing potentially transformative therapies to patients with beta thalassemia and sickle cell disease,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics.  "We look forward to discussing data from our recent work at the upcoming ASH conference.”

Details of the presentations are as follows:

Title: CRISPR/Cas9 – Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies (Abstract #3623)
Presenter: Bibhu Mishra, Ph.D., (Title)), CRISPR Therapeutics
Date:   Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center)
Session:  112. Thalassemia and Globin Gene Regulation: Poster III
   
Title:   Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia (Abstract #4708)
Presenter: Bill (Sven Ante) Lundberg, M.D., M.B.A, Chief Scientific Officer, CRISPR Therapeutics
Date:  Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center)
Session:   801. Gene Therapy and Transfer: Poster III
   

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.

MEDIA CONTACTS: Jennifer Paganelli W2O Group for CRISPR 347-658-8290 jpaganelli@w2ogroup.com INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR 339-970-2843 chris.brinzey@westwicke.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 136

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 60

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 637

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 107

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 21

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 208

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 251

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 103

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 49

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 224

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading

Top 5 Most Recently Viewed Articles

Leadership Transition at Ignitis Renewables Sparks Future Growth

Updated Category News Views 134

Leadership Transition at Ignitis Renewables AB “Ignitis grup?” has announced a significant change in leadership with the resignation of Thierry Aelens, the Chief Executive Officer (CEO) of its subsidiary, UAB “Ignitis Renewables.” Aelens will step down effective at the end of March 2025 for personal reasons and to pursue new career opportunities nearer to his...

Continue Reading
Katalyze AI Elevates Innovation with New Chief AI Officer

Updated Category News Views 206

Advancing Pharmaceutical Manufacturing with AI Leadership Katalyze AI has recently announced a pivotal move to strengthen its capabilities in the fast-evolving field of pharmaceutical manufacturing. The company has appointed Hannes Bretschneider as Chief AI Officer, signaling its commitment to advancing Agentic AI architecture. This strategic initiative aims to enhance...

Continue Reading
Iran's Strait Closure: Defense Stocks on Edge Amid Shipping Risks

Updated Category News Views 325

Iran announced the temporary closure of the Strait of Hormuz for live-fire drills, raising eyebrows across trading desks. This isn't just a geopolitical stunt; it’s a shot across the bow at U. S. military presence in the region, occurring right as indirect nuclear talks unfold with Washington. A maneuver like this sends ripples through markets that thrive on stability,...

Continue Reading
Aphaia Pharma's Engagement in Revolutionary Obesity Forum

Updated Category News Views 117

Aphaia Pharma's Engagement in Revolutionary Obesity Forum Aphaia Pharma, a leading clinical-stage biopharmaceutical company, is making waves in the field of treatments for obesity and related metabolic disorders. The company has announced that its Chief Scientific Officer, Dr. Steffen-Sebastian Bolz, will share insights during a panel discussion at the much-anticipated...

Continue Reading
U.S. Strives to Diminish China's Dominance in Rare Earths

Updated Category News Views 216

Understanding the Importance of Rare Earth Elements In recent discussions, the significance of rare earth elements (REEs) has come to the forefront of international policy. These elements play a crucial role in various sectors, from technology to defense. Currently, China holds a dominant position in the production and refinement of these vital minerals, controlling...

Continue Reading